XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...

CALGARY, Alberta, Jan. 17, 2025 (GLOBE NEWSWIRE) -- ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), ...

Diagnosis Tophaceous gout associated with urate nephropathy in a patient intolerant to allopurinol ... Despite concurrent treatment with diclofenac 75 mg daily and codeine 30–60 mg daily ...

Dr. Allen Davidoff commented,“Oxypurinol has been demonstrated to be safe and effective in clinical studies focused on the treatment of individuals with gout who are intolerant to allopurinol.

Previously, oxypurinol was granted ODD for allopurinol intolerant gout. Dr. Allen Davidoff commented, “Oxypurinol has been demonstrated to be safe and effective in clinical studies focused on the ...

FOR centuries, gout has been a deeply misunderstood disease, associated only with jolly, indulgent, and often big men. When Henry VIII was diagnosed, it became firmly entrenched in popular belief ...

The new drug development program - XRx-026 - will focus on the treatment of individuals who have gout and are intolerant to allopurinol. With the clinical development of XORLOTM 1 having advanced ...

XORTX Therapeutics (XRTX) announces the launch of a new late stage program to treat gout. The new drug development program – XRx-026 – will ...

Febuxostat is a second-line option for patients with gout who are unable to take allopurinol due to hypersensitivity ... Febuxostat is not recommended for the treatment of patients with secondary ...